Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche reports positive study results for MabThera

Roche reports positive study results for MabThera

31st January 2008

Roche has reported that MabThera has met its primary endpoint in improving disease symptoms in patients with rheumatoid arthritis (RA).

Following the release of Phase III study data, the Swiss pharmaceutical form announced that MabThera (rituximab) can now be used safely and effectively as a biologic therapy to improve the symptoms of (RA).

As part of the Serene study, the Phase III trial investigated patients suffering from RA who had experienced an inadequate response to methotrexate (MTX) therapy – a common RA drug.

MabThera was shown to meet its primary endpoint by demonstrating that significantly more patients achieved an improvement in disease signs and symptoms with Mabthera in combination with MTX compared to MTX alone.

William M Burns, chief executive officer of the pharmaceutical division at Roche, described the results as “encouraging” which showed MabThera to be a promising alternative to current treatment options.

“These data support the potential for MabThera to be used earlier in the course of treatment for RA,” he added.

MabThera is currently the only selective B cell therapy which is licensed for the treatment of patients suffering from RA.

Also this week, Roche has announced that Avastin (bevacizumab), its anti-angiogenic agent for patients suffering from metastatic colorectal cancer, has received a broad label extension from the European commission for wider use.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.